These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 27913578)

  • 1. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
    Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
    Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
    Kobayashi Y; Fujino T; Nishino M; Koga T; Chiba M; Sesumi Y; Ohara S; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    J Thorac Oncol; 2018 May; 13(5):727-731. PubMed ID: 29410323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
    Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
    Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
    Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
    Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
    Ercan D; Choi HG; Yun CH; Capelletti M; Xie T; Eck MJ; Gray NS; Jänne PA
    Clin Cancer Res; 2015 Sep; 21(17):3913-23. PubMed ID: 25948633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
    Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
    Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
    Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
    J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
    Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
    Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
    Niederst MJ; Hu H; Mulvey HE; Lockerman EL; Garcia AR; Piotrowska Z; Sequist LV; Engelman JA
    Clin Cancer Res; 2015 Sep; 21(17):3924-33. PubMed ID: 25964297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
    Lee C; Kim M; Kim DW; Kim TM; Kim S; Im SW; Jeon YK; Keam B; Ku JL; Heo DS
    Cancer Res Treat; 2022 Jan; 54(1):140-149. PubMed ID: 33940786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
    Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
    Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
    Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
    Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.
    Nakamura T; Nakashima C; Komiya K; Kitera K; Hirai M; Kimura S; Aragane N
    PLoS One; 2018; 13(12):e0209384. PubMed ID: 30550608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
    Janjigian YY; Smit EF; Groen HJ; Horn L; Gettinger S; Camidge DR; Riely GJ; Wang B; Fu Y; Chand VK; Miller VA; Pao W
    Cancer Discov; 2014 Sep; 4(9):1036-45. PubMed ID: 25074459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR
    Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
    Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
    Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
    Chen ZW; Lin G; Shih HJ; Wu CE
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.